SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Zhou Wenjing) "

Sökning: WFRF:(Zhou Wenjing)

  • Resultat 1-10 av 27
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Karlsson, E., et al. (författare)
  • Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
  • 2014
  • Ingår i: European Journal of Cancer. - : Elsevier. - 1879-0852 .- 0959-8049. ; 50:3, s. 517-524
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. In addition, impact on survival has been demonstrated. The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event. Materials and methods: The cohort includes 1504 patients, diagnosed with a primary DCIS between 1986 and 2004. Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. ER and PR were identified by immunohistochemistry (IHC) and HER2 by silver-enhanced in situ hybridisation (SISH) as well as IHC. Results: ER (n = 112), PR (n = 113) and HER2 (n = 114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively. The receptor conversion was both from negative to positive and from positive to negative with no general pattern being seen in spite of sub-dividing into in situ relapse and invasive relapse. However, primary DCIS was HER2 positive in 40.3% whereas in situ and invasive relapses were HER2 positive in 42.9% and 34.5% respectively. Conclusions: Receptor conversion for ER, PR and HER2 status occurred between primary DCIS and corresponding local relapse in 10-30%. This study could not confirm that HER2 overexpression in primary DCIS had any impact on tumour progression to invasive cancer which has been proposed. (C) 2013 Elsevier Ltd. All rights reserved.
  •  
2.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.
  • 2009
  • Ingår i: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - : American Association for Cancer Research. - 1538-7755 .- 1055-9965. ; 18, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size
  •  
3.
  •  
4.
  •  
5.
  • Borgquist, Signe, et al. (författare)
  • The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
  • 2015
  • Ingår i: BMC Cancer. - : BioMed Central (BMC). - 1471-2407 .- 1471-2407. ; 15
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. The role of HER2 in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to in situ recurrences. Our aim was to study HER2 as a prognostic factor in a large population based cohort of DCIS with long-term follow-up. Methods: All 458 patients diagnosed with a primary DCIS 1986-2004 in two Swedish counties were included. Silver-enhanced in situ hybridisation (SISH) was used for detection of HER2 gene amplification and protein expression was assessed by immunohistochemistry (IHC) in tissue microarrays. HER2 positivity was defined as amplified HER2 gene and/or HER2 3+ by IHC. HER2 status in relation to new ipsilateral events (IBE) and Invasive Breast Cancer Recurrences, local or distant (IBCR) was assessed by Kaplan-Meier survival analyses and Cox proportional hazards regression models. Results: Primary DCIS was screening-detected in 75.5 % of cases. Breast conserving surgery (BCS) was performed in 78.6 % of whom 44.0 % received postoperative radiotherapy. No patients received adjuvant endocrine-or chemotherapy. The majority of DCIS could be HER2 classified (N = 420 (91.7 %)); 132 HER2 positive (31 %) and 288 HER2 negative (69 %)). HER2 positivity was related to large tumor size (P = 0.002), high grade (P < 0.001) and ER-and PR negativity (P < 0.001 for both). During follow-up (mean 184 months), 106 IBCRs and 105 IBEs were identified among all 458 cases corresponding to 54 in situ and 51 invasive recurrences. Eighteen women died from breast cancer and another 114 had died from other causes. The risk of IBCR was statistically significantly lower subsequent to a HER2 positive DCIS compared to a HER2 negative DCIS, (Log-Rank P = 0.03, (HR) 0.60 (95 % CI 0.38-0.94)). Remarkably, the curves did not separate until after 10 years. In ER-stratified analyses, HER2 positive DCIS was associated with lower risk of IBCR among women with ER negative DCIS (Log-Rank P = 0.003), but not for women with ER positive DCIS. Conclusions: Improved prognostic tools for DCIS patients are warranted to tailor adjuvant therapy. Here, we demonstrate that HER2 positive disease in the primary DCIS is associated with lower risk of recurrent invasive breast cancer.
  •  
6.
  • Bremer, Troy (författare)
  • A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
  • 2018
  • Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 24:23, s. 5895-5901
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Ductal carcinoma in situ (DCIS) patients and their physicians currently face challenging treatment decisions with limited information about the individual's subsequent breast cancer risk or treatment benefit. The DCI-SionRT biological signature developed in this study provides recurrence risk and predicts radiotherapy (RT) benefit for DCIS patients following breast-conserving surgery (BCS). Experimental Design: A biological signature that calculates an individualized Decision Score (DS) was developed and cross-validated in 526 DCIS patients treated with BCS = RT. The relationship was assessed between DS and 10-year risk of invasive breast cancer (IBC) or any ipsilateral breast event (IBE), including IBC or DCIS. RT benefit was evaluated by risk group and as a function of DS. Results: The DS was significantly associated with IBC and IBE risk, HR (per 5 units) of 4.2 and 3.1, respectively. For patients treated without RT, DS identified a Low Group with 10-year IBC risk of 4% (7% IBE) and an Elevated Risk Group with IBC risk of 15% (23% IBE). In analysis of DS and RT by group, the Elevated Risk Group received significant RT benefit, HR of 0.3 for IBC and IBE. In a clinicopathologically low-risk subset, DS reclassified 42% of patients into the Elevated Risk Group. In an interaction analysis of DS and RT, patients with elevated DS had significant RT benefit over baseline. Conclusions: The DS was prognostic for risk and predicted RT benefit for DCIS patients. DS identified a clinically meaningful low-risk group and a group with elevated 10-year risks that received substantial RT benefit over baseline.
  •  
7.
  • Butt, Salma, et al. (författare)
  • The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy.
  • 2014
  • Ingår i: Annals of Surgical Oncology. - : Springer. - 1534-4681 .- 1068-9265. ; 21:9, s. 2911-2919
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with ductal carcinoma-in-situ (DCIS) are currently not prescribed adjuvant systemic treatment after surgery and radiotherapy. Prediction of DCIS patients who would benefit from radiotherapy is warranted. Statins have been suggested to exert radio-sensitizing effects. The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. The aim of this study was to examine HMGCR expression in DCIS and study its treatment predictive value.
  •  
8.
  • Lin, Jiuluan, et al. (författare)
  • Novel Method to Identify the Precentral Gyrus and Its Detailed Functional Distribution in Real Brain Surfaces Using Reconstructed 3D Brain Surface Imaging
  • 2015
  • Ingår i: JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS. - 2156-7018. ; 5:2, s. 216-222
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To study the use of reconstructed 3D brain surface imaging (RBSI) to identify the precentral gyrus and its detailed functional distribution in epileptic patients. Method: A total of 12 refractory epilepsy cases that need intracranial electrode implantation were studied. In these patients, pre-operative magnetic resonance imaging (MRI) and functional MRI (fMRI) were conducted, and a cranial computed tomography (CT) scan was performed after electrode implantation. The RBSI was accomplished using Brain Voyager software based on MRI data, and then the 3D brain surface was integrated with the subdural electrode CT scan. The precentral gyrus was found in the reconstructed brain surface imaging according to their anatomical shape, and then were identified in the surgical field by comparing the exposed gyrus in the RBSI with the help of intraoperative photographs. Results: Total 12 cases of precentral gyrus was found and marked in the RBSI. There were 101 electrodes covering the precentral gyrus and 73 (72%) of them had motor response to electrical stimulation. In the contrast, (the area which is 1 cm ahead of the precentral gyrus), the motor response rate was 13% (17/130) (p < 0.05). During fMRI, 100% of the precentral gyrus and 58% (7/12) of post central gyrus was activated during hand movement. Whereas, no activation of the areas ahead of precentral gyrus was seen showing a significant difference between precentral gyrus and gyrus ahead. Conclusion: Our results demonstrated that using RBSI technique, it is possible to identify the precentral gyrus with precision.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 27
  • [1]23Nästa
Typ av publikation
tidskriftsartikel (24)
annan publikation (2)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (20)
övrigt vetenskapligt (7)
Författare/redaktör
Zhou, Wenjing (19)
Amini, Rose-Marie (16)
Wärnberg, Fredrik (16)
Blomqvist, Carl (11)
Fjällskog, Marie Lou ... (9)
Jirström, Karin (9)
visa fler...
Jirstrom, Karin (6)
Sollie, Thomas (6)
Warnberg, Fredrik (4)
Sorlie, Therese (4)
Ahlin, Cecilia (3)
Abdsaleh, Shahin (3)
Borgquist, Signe (3)
Johansson, Christine (3)
Holmqvist, Marit (3)
Sørlie, Therese (3)
Savala, Jess (3)
Barry, Todd (3)
Lyle, Stephen (3)
Linke, Steven P. (3)
Zhou, Yinhua (3)
Tot, Tibor (3)
Bergh, J (2)
Zhou, W. (2)
Ringberg, Anita (2)
Sandelin, K (2)
Warnberg, F (2)
Holmberg, Lars (2)
Karlsson, E (2)
Zhang, Fengling, 196 ... (2)
Inganäs, Olle, 1951- (2)
Jirstrom, K (2)
Butt, Salma (2)
Ågren, Hans (2)
Zhang, Haibo (2)
Tvingstedt, Kristofe ... (2)
Appelgren, J (2)
Baryshnikov, Gleb V. (2)
Kuklin, Artem V. (2)
Fjallskog, Marie-Lou ... (2)
Whitworth, Pat (2)
Bremer, Troy M. (2)
Noskina, Yelina (2)
Walters, Stephanie C ... (2)
Taglienti, Cherie (2)
Simin, Karl (2)
Zhao, Xue (2)
Yang, Ziqiong (2)
Zhou, Xiaohai (2)
Zhou, Wenjing, 1979- (2)
visa färre...
Lärosäte
Uppsala universitet (19)
Lunds universitet (7)
Linköpings universitet (3)
Kungliga Tekniska Högskolan (2)
Örebro universitet (1)
Karlstads universitet (1)
visa fler...
Naturhistoriska riksmuseet (1)
visa färre...
Språk
Engelska (26)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (18)
Naturvetenskap (4)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy